Acting On Nitrogen-containing Compound As Donor (1.2, 1.5, 1.7) Patents (Class 435/191)
  • Patent number: 11224584
    Abstract: Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: January 18, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tiffany J. Braley, Benjamin Segal, Ronald D. Chervin
  • Patent number: 11098289
    Abstract: Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: August 24, 2021
    Assignee: MedImmune, LLC
    Inventors: Manuel Baca, Andrew C. Nyborg
  • Patent number: 11021690
    Abstract: A mutant-type uricase, PEG modified mutant-type uricase, and application thereof. The mutant-type uricase has a cysteine residue introduced by recombination, the cysteine residue is located at an inactive region of the uricase, and one or more PEGs are coupled to the mutant-type uricase. The resulting PEGylated mutant-type uricase has characteristics of a half-life extension, product uniformity, and stable enzyme activity. Therefore, the present invention has a wide future application range.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: June 1, 2021
    Assignee: SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.
    Inventors: Yun Jiang, Linqiu Huang, Jueren Lou
  • Patent number: 10736911
    Abstract: Compounds and methods are provided for the treatment of pathogenic virus infections or cancer. The formulations combine an inhibitor of de novo pyrimidine synthesis, and an inhibitor of a pyrimidine salvage pathway enzyme.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: August 11, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Richard Deans, Ayse Okesli, David Morgens, Chaitan Khosla, Michael C. Bassik
  • Patent number: 10149461
    Abstract: Porcine animals, tissue and organs as well as cells and cell lines derived from such animals are provided that lack functional endogenous immunoglobulin loci and are deficient in immunoglobulin expression and B-cells. These animals are useful as model systems for research and for development of new pharmaceutical and biological agents. In addition, methods are provided to prepare such animals.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: December 11, 2018
    Assignee: Revivicor, Inc.
    Inventors: David L. Ayares, Michael Mendicino, Kevin Wells, Amy S. Dandro
  • Patent number: 10023836
    Abstract: In order to provide a culture medium eliminating variation by lot of component concentrations, the present invention provides a culture medium, and preferably a chemical-synthetic culture medium, imparting a proliferation ability to yeast that is equivalent to or greater than that of a YPD culture medium. A culture medium is provided which includes sugars as a carbon source capable of being assimilated by yeast; amino acids as a nitrogen source; vitamins; inositol; zinc ion (Zn2+); potassium ion (K+), and magnesium ion (Mg2+), and in which inositol concentration is between 50 and 10,000 mg/L.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 17, 2018
    Assignees: YAMAGUCHI UNIVERSITY, KOHJIN LIFE SCIENCES CO., LTD.
    Inventor: Rinji Akada
  • Patent number: 9750675
    Abstract: The present invention relates to the use of a source of green light for activating L-amino acid oxidase in the presence of at least one substrate of this enzyme in order to stimulate the energy metabolism of the cells of the skin, to stimulate their replacement and thus to improve the appearance of the skin and hair, in particular to prevent and/or treat cutaneous signs of ageing of the skin and hair.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: September 5, 2017
    Assignee: L'OREAL
    Inventors: Julien Laboureau, Quang Lan Nguyen
  • Patent number: 9388395
    Abstract: The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: July 12, 2016
    Assignee: Codexis, Inc.
    Inventors: Jovana Nazor, Derek Smith, Michael Crowe, Shiwei Song, Steven J. Collier
  • Patent number: 9314746
    Abstract: Hydrophilic porous substrates, methods of making hydrophilic porous substrates from hydrophobic polymers are disclosed.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: April 19, 2016
    Assignee: 3M Innovative Properties Company
    Inventors: Clinton P. Waller, Jr., Douglas E. Weiss
  • Patent number: 9034629
    Abstract: The present disclosure identifies methods and compositions for modifying photoautotrophic organisms as hosts, such that the organisms efficiently produce alkanes, and in particular the use of such organisms for the commercial production of alkanes and related molecules. Other materials, methods, and compositions are also described.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: May 19, 2015
    Assignee: Joule Unlimited Technologies, Inc.
    Inventors: Frank Anthony Skraly, Ning Li
  • Publication number: 20150132807
    Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Inventors: Nicholas J. Agard, Oscar Alvizo, Melissa Ann Mayo, Stefanie Ng Minor, James Nicholas Riggins, Jeffrey C. Moore
  • Publication number: 20150118700
    Abstract: This invention provides an amadoriase having high reactivity with ?-fructosyl hexapeptide (?F6P) derived from the ?-chain amino terminus of glycated hemoglobin (HbAlc), which enables satisfactory quantification of ?F6P cleaved from HbAlc. A novel amadoriase is derived from the amadoriase of the genus Coniochaeta by substitution of one or more amino acids at positions selected from the group consisting of positions 62, 63, 102, 106, 110, 113, 355, and 419. Such amadoriase enables rapid, simple, accurate, and satisfactory quantification of ?F6P cleaved from HbAlc. With the use of such amadoriase, a method for measurement of HbAlc by an enzymatic method and a kit for measurement of HbAlc that are based on the same principle as used in the conventional standard method and excellent in terms of the relevance with the standard method.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 30, 2015
    Inventors: Atsushi Ichiyanagi, Yosuke Masakari
  • Patent number: 9017980
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: April 28, 2015
    Assignee: Crealta Pharmaceuticals LLC
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Publication number: 20150111268
    Abstract: Recombinant butyraldehyde dehydrogenases (Blds) with improved production of 1,4-BDO, as well as recombinant microorganisms comprising polynucleotides encoding the recombinant Blds, and methods of producing 1,4-BDO by using the recombinant microorganisms.
    Type: Application
    Filed: October 1, 2014
    Publication date: April 23, 2015
    Inventors: Jinhwan Park, Pyungcheon Lee, Jaechan Park, Youngmin Lee, Wooyong Lee, Jinwoo Park, Kwangmyung Cho, Heejin Hwang
  • Publication number: 20150105456
    Abstract: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Inventors: Daria Mochly-Rosen, Che-Hong Chen, Xiaohu Ouyang
  • Publication number: 20150064757
    Abstract: The disclosure relates to variant carboxylic acid reductase (CAR) enzymes for the improved production of fatty alcohols in recombinant host cells.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 5, 2015
    Applicant: REG Life Sciences, LLC
    Inventors: Derek L. Greenfield, Elizabeth J. Clarke, Eli S. Groban, Vikranth Arlagadda, Sungwon Lee, Xuezhi Li, Zhihao Hu
  • Patent number: 8962271
    Abstract: In one form, a fructosyl peptidyl oxidase derived from a budding yeast Phaeosphaeria nodorum for assaying a glycated protein in a sample is provided. The fructosyl peptidyl oxidase has higher activity toward fructosyl valine as well as fructosyl valyl histidine, and may be useful in assaying HbA1c with higher sensitivity and specificity. Still, other forms include unique methods, techniques, systems and devices involving a fructosyl peptidyl oxidase.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: February 24, 2015
    Assignees: Roche Diagnostics Operations, Inc., Ultizyme International, Ltd.
    Inventors: Kazunori Ikebukuro, Sode Koji
  • Publication number: 20150037842
    Abstract: The disclosure relates to a Gram negative bacterial cell that is transformed with a nucleic acid molecule that encodes a Gram positive twin-arginine translocase and including methods for the production of polypeptides.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Inventor: Colin Robinson
  • Publication number: 20150030601
    Abstract: The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a UBA3, UAE, or UBA6, or other E1 enzyme variant gene has been introduced or disrupted. The invention still further provides isolated UBA3, UAE, or UBA6, or other E1 enzyme variant proteins, fusion proteins, antigenic peptides and anti-UBA3, UAE, or UBA6, or other E1 enzyme variant antibodies. The invention provides methods to identify agents that inhibit UBA3, UAE, or UBA6, or other E1 enzyme variant expression or activity. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 5, 2012
    Publication date: January 29, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Benjamin Stone Amidon, James E. Brownell, James M. Gavin, Erik M. Koenig, Michael D. Sintchak, Peter G. Smith
  • Patent number: 8940295
    Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 27, 2015
    Assignee: Oxthera Intellectual Property AB
    Inventors: Harmeet Sidhu, Aaron Blake Cowley, Carl-Gustaf Golander, Qingshan Li
  • Publication number: 20150004150
    Abstract: The present invention relates to a method of reducing the level of uric acid in a subject, which comprises administering to said subject an effective amount of a fermentation product of Tenacibaculum sp. Also provided are a method of preventing and/or treating a disease or disorder related to hyperuricemia, a method of increasing the digestion of uric acid and a method of producing uricase.
    Type: Application
    Filed: June 25, 2014
    Publication date: January 1, 2015
    Inventors: Mei-Huei Chen, Siao-Jhen Chen, Hsun-Yin Hsu, Yen-Lin Chen, Kai-Ping Chen, Yi-Jen Yech, Li-Ting Wang, Hing-Yuen Chan
  • Patent number: 8921043
    Abstract: Compositions and methods are described to modify Family B DNA polymerases that contain residual exonuclease activity that interferes with sequencing techniques and with detection of single nucleotide polymorphisms. The compositions are mutant proteins with reduced exonuclease activity compared with presently available “exo?” polymerases, and a sensitive screening assay that enables an assessment of exonuclease activity of any synthetic DNA polymerase.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: December 30, 2014
    Assignee: New England Biolabs, Inc.
    Inventor: Andrew Gardner
  • Patent number: 8921044
    Abstract: Compositions and methods are described to modify Family B DNA polymerases that contain residual exonuclease activity that interferes with sequencing techniques and with detection of single nucleotide polymorphisms. The compositions are mutant proteins with reduced exonuclease activity compared with presently available “exo?” polymerases, and a sensitive screening assay that enables an assessment of exonuclease activity of any synthetic DNA polymerase.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: December 30, 2014
    Assignee: New England BioLabs, Inc.
    Inventor: Andrew Gardner
  • Publication number: 20140363414
    Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 11, 2014
    Applicants: Mountain View Pharmaceuticals, Inc., Duke University
    Inventors: Merry R. SHERMAN, Mark G.P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
  • Publication number: 20140356389
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Application
    Filed: June 2, 2014
    Publication date: December 4, 2014
    Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRL
    Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
  • Publication number: 20140356928
    Abstract: An amadoriase having a substitution or a deletion of one or more amino acid residues at positions corresponding to amino acids selected from the group consisting of three amino acid residues from the carboxyl terminal and amino acids at positions 151, 43, 53, 267, 350, 185, 196, 299 and 323 in the amino acid sequence of amadoriase derived from the Coniochaeta species indicated in SEQ ID NO: 1. The amadoriase having a heat resistance which is superior to that of a conventional amadoriase.
    Type: Application
    Filed: December 27, 2012
    Publication date: December 4, 2014
    Inventors: Yosuke Masakari, Atsushi Ichiyanagi
  • Publication number: 20140357727
    Abstract: The present disclosure provides methods useful for producing fatty alcohol compositions from recombinant host cells. The disclosure further provides fatty acyl-CoA reductase (FAR) variant enzymes, polynucleotides encoding the FAR variant enzymes, and vectors and host cells comprising polynucleotides encoding the FAR variant enzymes.
    Type: Application
    Filed: December 13, 2012
    Publication date: December 4, 2014
    Inventors: Louis A. Clark, Kristian Karlshoej, Patricia Choudhary
  • Publication number: 20140349327
    Abstract: Object An object of the present invention is to provide a highly stable FVHO preparation and a low-hygroscopicity dried FVHO preparation. Means for achieving the object A method for producing a FVHO preparation comprising a step of allowing at least one member selected from phosphoric acid, casein peptone, D-glucosamine hydrochloride, melibiose, sorbose, lactose, fructose, melezitose, glucono-1,5-lactone, and ribitol; and a method for producing a dried FVHO preparation, comprising a step of allowing Bicine to coexist.
    Type: Application
    Filed: January 10, 2013
    Publication date: November 27, 2014
    Applicant: TOYOBO CO., LTD.
    Inventors: Rie Hirao, Takahide Kishimoto, Shusaku Yanagidani
  • Publication number: 20140344997
    Abstract: Disclosed are polynucleotides encoding polypeptides that comprise the biosynthetic pathway for lignin in the jute plant. The present invention relates generally to the field of plant lignin biosynthesis genes, polypeptides encoded by such genes, and the use of such polynucleotide and polypeptide sequences for controlling plant lignin production. Also disclosed are methods for using the polynucleotides and polypeptides to influence the quality and amount of fiber produced by jute.
    Type: Application
    Filed: April 25, 2012
    Publication date: November 20, 2014
    Applicant: Bangladesh Jute Research Institute
    Inventors: Maqsudul Alam, Haseena Khan, Mahboob Zaman, Mohammed K. Uddin, Mohammed S. Haque, Mohammed S. Islam, Muhammed S. Azam
  • Publication number: 20140302583
    Abstract: DNA constructs as well as methods for the production of unicellular organisms capable of producing hydrogen peroxide resistance proteins are disclosed. DNA constructs as well as methods for integration of the DNA constructs into the genomes of unicellular organisms for the expression of hydrogen peroxide production proteins are also disclosed. In addition, DNA constructs as well as methods for integration of the DNA constructs into the genomes of unicellular organisms for the expression of hydrogen peroxide resistance and hydrogen peroxide production proteins are disclosed.
    Type: Application
    Filed: October 4, 2012
    Publication date: October 9, 2014
    Inventors: Stephen K. Herbert, Levi G. Lowder
  • Patent number: 8841096
    Abstract: The invention relates to a method for the amination of at least one keto group in a multicyclic ring system comprising at least one keto group into an amino group, using at least one enzyme E having transaminase activity.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: September 23, 2014
    Assignee: Evonik Degussa GmbH
    Inventors: Volker Sieber, Katrin Grammann, Broder Ruehmann, Thomas Haas, Jan Christoph Pfeffer, Kai Doderer, Claudia Rollmann, Arne Skerra, Christian Rausch, Alexandra Lerchner
  • Patent number: 8828699
    Abstract: Disclosed are: a eukaryotic amadoriase which is prepared by introducing a mutation into DNA encoding a eukaryotic amadoriase derived from a microorganism belonging to the genus Coniochaeta or Eupenicillium so as to introduce a substitution into a specific amino acid residue in the eukaryotic amadoriase, thereby overcoming the defect associated with thermal stability; a gene or recombinant DNA for the eukaryotic amadoriase; and a process for production of a eukaryotic amadoriase having excellent thermal stability.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: September 9, 2014
    Assignee: Kikkoman Corporation
    Inventors: Kozo Hirokawa, Atsushi Ichiyanagi
  • Patent number: 8809024
    Abstract: A process for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV is provided which employs a BOC-protected amine of the structure prepared by subjecting an acid of the structure to reduce amination by treating the acid with ammonium formate, nicotinamide adenine dinucleotide, dithiothreitol and partially purified phenylalanine dehydrogenase/formate dehydrogenase enzyme concentrate (PDH/FDH) and without isolating treating the resulting amine of the structure 2 with di-tert-butyl dicarbonate to form the BOC-protected amine.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: August 19, 2014
    Assignee: AstraZeneca AB
    Inventors: Michael Politino, Matthew M. Cadin, Jason G. Chen
  • Publication number: 20140201868
    Abstract: The present invention relates to fungi of Acremonium spp, wherein said fungi are purified or isolated from plants of the Brachiaria-Urochloa complex and wherein, when said fungi are inoculated into a plant, said plant has improved resistance to diseases and/or pests relative to an uninocualated control plant. The present invention also relates to plants inoculated with such fungi, products produced by the fungi and related genes, proteins and methods.
    Type: Application
    Filed: June 1, 2012
    Publication date: July 17, 2014
    Applicant: AGRICULTURE VICTORIA SERVICES PTY LTD
    Inventors: German Carlos Spangenberg, Kathryn Michaela Guthridge
  • Publication number: 20140193869
    Abstract: The present disclosure relates, in some aspects, to cell-free methods and systems for large-scale conversion of methane to isobutanol, comprising combining, in a bioreactor at elevated pressure, methane, oxygen, and cell lysates containing methane monooxygenase, methanol dehydrogenase, and enzymes that catalyze the conversion of formaldehyde to isobutanol, to form a cell-free reaction mixture, and incubating under suitable conditions the cell-free reaction to convert methane to isobutanol.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 10, 2014
    Applicant: GreenLight Biosciences, Inc.
    Inventors: William Jeremy Blake, James R. Swartz
  • Publication number: 20140154744
    Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.
    Type: Application
    Filed: July 11, 2012
    Publication date: June 5, 2014
    Applicant: YALE UNIVERSITY
    Inventors: Dieter Soll, Caroline Aldag, Michael Hohn
  • Patent number: 8721853
    Abstract: In one form, a fructosyl peptidyl oxidase derived from a budding yeast Phaeosphaeria nodorum for assaying a glycated protein in a sample is provided. The fructosyl peptidyl oxidase has higher activity toward fructosyl valine as well as fructosyl valyl histidine, and may be useful in assaying HbA1c with higher sensitivity and specificity. Still, other forms include unique methods, techniques, systems and devices involving a fructosyl peptidyl oxidase.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: May 13, 2014
    Assignees: Roche Diagnostics Operations, Inc., Ultizyme International, Ltd
    Inventors: Kazunori Ikebukuro, Koji Sode
  • Patent number: 8716244
    Abstract: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: May 6, 2014
    Assignee: Sciotec Diagnostic Technologies GmbH
    Inventors: Albert Missbichler, Franz Gabor, Herwig Reichl
  • Publication number: 20140093929
    Abstract: The present disclosure provides methods useful for producing fatty alcohol compositions from recombinant host cells. The disclosure further provides variant fatty acyl-CoA reductase (FAR) enzymes, polynucleotides encoding the variant FAR enzymes, and vectors and host cells comprising the same.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 3, 2014
    Inventors: Behnaz Behrouzian, Louis Clark, Yihui Zhu, Michael Clay, Kristian Karlshoej
  • Publication number: 20140057333
    Abstract: The present invention encompasses: [1] a DNA encoding the protein of any one of (i) a protein comprising the sequence of SEQ ID NO:1; (ii) a protein comprising a sequence with one to ten amino acid deletions, substitutions, or additions in the sequence of SEQ ID NO:1, and having fructosyl peptide oxidase activity; (iii) a protein comprising a sequence having 99% or higher homology to the sequence of SEQ ID NO:1, and having fructosyl peptide oxidase activity; and (iv) a protein having fructosyl peptide oxidase activity, which is encoded by an expression plasmid harbored by the strain deposited under Accession No. FERM BP-11026; [2] a DNA comprising the of SEQ ID NO: 2; and [3] a DNA that hybridizes under stringent conditions with a DNA comprising a sequence complementary to SEQ ID NO: 2, where the DNA encodes a protein having fructosyl peptide oxidase activity.
    Type: Application
    Filed: October 2, 2012
    Publication date: February 27, 2014
    Applicant: KYOWA MEDEX CO., LTD.
    Inventors: Toshiko Aisaka, KYOWA MEDEX CO., LTD.
  • Patent number: 8618267
    Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: December 31, 2013
    Assignees: Mountain View Pharmaceuticals, Inc., Duke University
    Inventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
  • Publication number: 20130336951
    Abstract: The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of inhibiting AMPA receptor mediated excitotoxicity using the polypeptides and nucleic acids are also disclosed.
    Type: Application
    Filed: August 27, 2013
    Publication date: December 19, 2013
    Applicant: Centre For Addiction And Mental Health
    Inventor: Fang LIU
  • Publication number: 20130330803
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 12, 2013
    Applicant: Savient Pharmaceuticals, Inc.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Publication number: 20130323772
    Abstract: Methods and materials related to producing 3-HP as well as other organic compounds are disclosed. Specifically, isolated nucleic acids, polypeptides, host cells, and methods and materials for producing 3-HP and other organic compounds are disclosed.
    Type: Application
    Filed: June 25, 2013
    Publication date: December 5, 2013
    Applicant: Cargill, Incorporated
    Inventors: Ravi R. Gokarn, Olga V. Selifonova, Holly Jean Jessen, Steven John Gort, Thorsten Selmer, Wolfgang Buckel
  • Patent number: 8586535
    Abstract: The present invention provides a humanized recombinant uricase and mutants thereof, wherein the humanized recombinant uricase is a chimeric protein which comprises amino acids of non-human mammal uricase and amino acids of human uricase. The humanized recombinant unease and mutants thereof have reduced immunogenicity in human, and can be used for the treatment of hyperuricemia and gout.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: November 19, 2013
    Assignee: Chongqing Fagen Biomedical Inc.
    Inventors: Kai Fan, Chun Zhang, Xuefeng Ma, Xiang Mei, Chunlan Hu
  • Patent number: 8586338
    Abstract: Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: November 19, 2013
    Assignees: 3M Innovative Properties Company, Wisconsin Alumni Research Foundation
    Inventors: Mark R. Etzel, Yi He, Steven M. Heilmann, Jerald K. Rasmussen, Kannan Seshadri, Simon K. Shannon, Clinton P. Waller, Jr., Douglas E. Weiss
  • Publication number: 20130302859
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Application
    Filed: May 9, 2013
    Publication date: November 14, 2013
    Applicant: CODEXIS,INC.
    Inventors: CHEN Haibin, Steven J. Collier, Jovana NAZOR, Joly SUKUMARAN, Derek SMITH, Jeffrey C. MOORE, Gregory HUGHES, Jacob JANEY, Gjalt HUISMAN, Scott NOVICK, Nicholas AGARD, Oscar ALVIZO, Gregory COPE, Wan Lin YEO, Stephanie NG
  • Publication number: 20130295011
    Abstract: The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: More particularly, although not exclusively, said enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods.
    Type: Application
    Filed: July 18, 2011
    Publication date: November 7, 2013
    Applicants: VICTORIA LINK LIMITED, AUCKLAND UNISERVICES LIMITED
    Inventors: Christopher Paul Guise, David Francis Ackerley, Amir Ashoorzadeh, Janine Naomi Copp, Jack Urquhart Flanagan, Alexandra Marie Mowday, Adam Vorn Patterson, Gareth Adrian Prosser, Jeffrey Bruce Smaill, Sophie Phillipa Syddall, Elsie May Williams
  • Publication number: 20130273023
    Abstract: The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.
    Type: Application
    Filed: April 21, 2011
    Publication date: October 17, 2013
    Applicant: YALE UNIVERSITY
    Inventors: JIANCHAO XU, GARY DESIR
  • Patent number: RE45074
    Abstract: The present invention provides a method of pretreating a sample containing a glycated amine as an analyte, thereby enabling highly reliable measurement of a glycated amine. A glycated amino acid in the sample is degraded by causing a fructosyl amino acid oxidase (FAOD) to act thereon, and thereafter, a FAOD further is caused to act on the glycated amine as the analyte in the sample to cause a redox reaction. The amount of the glycated amine is determined by measuring the redox reaction. The substrate specificity of the FAOD caused to act on the glycated amino acid may be either the same as or different from that of the FAOD caused to act on the glycated amine. When using the same FAOD, a FAOD is caused to act on the glycated amino acid to degrade it, and thereafter, the sample is treated with a protease to inactivate the FAOD and also to degrade the glycated amine.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: August 12, 2014
    Assignee: ARKRAY, Inc.
    Inventors: Satoshi Yonehara, Tsuguki Komori